Further evidence of dopamine transporter dysregulation in ADHD: a controlled PET imaging study using altropane.

Article Details

Citation

Copy to clipboard

Spencer TJ, Biederman J, Madras BK, Dougherty DD, Bonab AA, Livni E, Meltzer PC, Martin J, Rauch S, Fischman AJ

Further evidence of dopamine transporter dysregulation in ADHD: a controlled PET imaging study using altropane.

Biol Psychiatry. 2007 Nov 1;62(9):1059-61. Epub 2007 May 23.

PubMed ID

17511972 [ View in PubMed

]

Abstract

BACKGROUND: The dopamine transporter (DAT) is known to be a key regulator of dopamine, and recent studies of genetics, treatment, and imaging have highlighted the role of DAT in attention-deficit/hyperactivity disorder (ADHD). The findings of in vivo neuroimaging of DAT in ADHD have been somewhat discrepant, however. METHOD: Dopamine transporter binding was measured using a highly selective ligand (C-11 altropane) and positron emission tomography (PET). The sample consisted of 47 well-characterized, treatment-naive, nonsmoking, non-comorbid adults with and without ADHD. Additionally, control subjects had few symptoms of ADHD. RESULTS: Results showed significantly increased DAT binding in the right caudate in adults with ADHD compared with matched control subjects without this disorder. CONCLUSIONS: These results confirm abnormal DAT binding in the striatum of adults with ADHD and provide further support that dysregulation of DAT may be an important component of the pathophysiology of ADHD.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Altropane	Sodium-dependent dopamine transporter	Protein	Humans	Unknown	Not Available	Details